A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older With an Extension Phase of up to 60 Months

Trial Profile

A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older With an Extension Phase of up to 60 Months

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2018

At a glance

  • Drugs Bis-choline tetrathiomolybdate (Primary)
  • Indications Hepatolenticular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS
  • Sponsors Wilson Therapeutics
  • Most Recent Events

    • 19 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 16 Feb 2018 According the Wilson Therapeutics media release, first patient has been enrolled in this study.
    • 10 Dec 2016 According to Wilson Therapeutics media release, company is planning to initiate the study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top